Zainab Mohammed Pharmacist - Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist Medicare: Not Enrolled in Medicare Practice Location: 12094 Calle De Medio Unit 138, El Cajon, CA 92019 Phone: 832-542-9012 |
Dr. Fadi Nimat Hasso, PHARMD, RPH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1299 Broadway, El Cajon, CA 92021 Phone: 619-441-8040 |
Melissa Rose Sandlin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2760 Fletcher Pkwy, El Cajon, CA 92020 Phone: 619-461-4411 |
Jihee Choi Lee, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 215 N 2nd St, El Cajon, CA 92021 Phone: 619-401-0761 Fax: 619-401-3435 |
Tariq Al-saleh Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 505 N Mollison Ave Ste 102, El Cajon, CA 92021 Phone: 619-457-0545 |
Ngoc B Tran, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1201 Avocado Ave, El Cajon, CA 92020 Phone: 619-440-1915 Fax: 619-440-1339 |
Lisa Tran Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2911 Jamacha Rd, El Cajon, CA 92019 Phone: 619-315-0016 |
News Archive
The International Osteoporosis Foundation will hold its 3rd IOF Regionals - Asia-Pacific Osteoporosis Meeting from December 13 to 16, 2012 in Kuala Lumpur, Malaysia. IOF looks forward to the participation of more than 1000 health professionals from varied fields including orthopaedics, endocrinology, rheumatology, gynaecology, radiology, rehabilitation and general practice.
Cardinal Health recently donated $1 million to Nationwide Children's Hospital to help advance the work and research of its Tissue Engineering Program.
Many breast cancer therapies cause damage to the heart. However, in the largest study of its kind so far, scientists from the German Cancer Research Center in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average population.
Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.
› Verified 9 days ago